

**In the Claims**

Applicant has submitted a new complete claim set. Claims 1-2, 14-15, 23-26 and 38-39 are pending in the application.

1. (Original) An isolated TgAMA-1 polypeptide molecule comprising an antigenic fragment of the polypeptide sequence set forth as amino acids SEQ ID NO:1.
2. (Original) A fusion protein comprising the antigenic polypeptide of claim 1.
3. (Withdrawn) An isolated TgAMA-1 nucleic acid molecule selected from the group consisting of:
  - (a) a fragment of the nucleotide sequence set forth as nucleotides 1-2507 of SEQ ID NO: 2 between 12 and 2506 nucleotides in length, and
  - (b) complements of (a),wherein the fragment encodes the isolated polypeptide of claim 1.
4. (Withdrawn) An expression vector comprising the isolated nucleic acid sequence of claim 3 operably linked to a promoter.
5. (Withdrawn) An expression vector comprising an isolated nucleic acid molecule of SEQ ID NO: 2. operably linked to a promoter.
6. (Withdrawn) A host cell transformed or transfected with the expression vector of any one of claims 4 and 5.
7. (Withdrawn) The host cell of claim 6, wherein the cell is an insect cell.
8. (Cancelled)

9. (Withdrawn) A transgenic non-human animal comprising the expression vector of any one of claims 4 and 5.

10-13. (Cancelled)

14. (Original) A vaccine composition comprising the isolated TgAMA-1 polypeptide of claim 1 and an adjuvant.

15. (Original) A vaccine composition comprising TgAMA-1 or a functionally active variant thereof, and an adjuvant.

16. (Cancelled)

17. (Withdrawn) A method for immunizing a subject comprising  
administering to the subject an effective amount for immunizing the subject of a vaccine of any one of claims 14 or 15.

18-19. (Cancelled)

20. (Withdrawn) The method of claim 17, wherein the subject is at risk of infection from *Toxoplasma gondii*.

21-22. (Cancelled)

23. (Original) A TgAMA-1 binding polypeptide that selectively binds to the isolated TgAMA-1 polypeptide of claim 1.

24. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide is an antibody or antigen-binding fragment of an antibody.

25. (Original) The TgAMA-1 binding polypeptide of claim 24, wherein the antibody or antigen-binding fragment specifically binds to a region comprising about 12 or more cysteine residues of the isolated polypeptide of claim 1.

26. (Original) The TgAMA-1 binding polypeptide of claim 23, wherein the binding polypeptide blocks entry of Toxoplasma parasite into a cell.

27-29. (Cancelled)

30. (Withdrawn) A method for treating a toxoplasma infection, comprising:  
administering to a subject in need of such treatment, an effective amount of a TgAMA-1 binding polypeptide of claim 23 to treat the toxoplasma infection.

31. (Withdrawn) The method of claim 30, wherein the TgAMA-1 binding polypeptide blocks the entry of Toxoplasma parasite into a cell.

32-33. (Cancelled)

34. (Withdrawn) A method for reducing the likelihood of a toxoplasma infection, comprising:  
administering to a subject in need of such treatment, an effective amount of a binding polypeptide of claim 23 to reduce the likelihood of toxoplasma infection.

35. (Withdrawn) The method of claim 34, wherein the binding polypeptide blocks the entry of Toxoplasma parasite into a cell.

36-37. (Cancelled)

38. (Previously Added) The vaccine composition of claim 14, wherein the vaccine is a proteosome vaccine.

Serial No.: 10/039,770  
Conf. No.: 9181

- 6 -

Art Unit: 1645

39. (Previously Added) The vaccine composition of claim 15, wherein the vaccine is a proteosome vaccine.